Lexicon Pharmaceuticals NASDAQ: LXRX reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA- HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabetes during the fourth quarter. Lexicon recorded a net loss of $31.8 million, or $0.07 per share, compared with net income of $3.3 million, or $0.01 per share, in the second quarter of 2025. The 2026 loss included ...